Core Viewpoint - The company anticipates achieving revenue of approximately RMB 90 million to 92 million for the fiscal year ending December 31, 2025, with total income and gains expected to reach around RMB 105 million to 110 million, marking a significant achievement in its first commercial year [1] Group 1 - The company's first commercial product, the Ken-Valve aortic valve system, has generated robust revenue in its inaugural year, attributed to its design and operational advantages that facilitate rapid adoption across various healthcare institutions [1] - The company has initiated paid clinical implantations of multiple structural heart intervention products overseas, receiving high praise from key opinion leaders and experts globally, addressing the long-standing unmet clinical needs in structural heart disease [1] Group 2 - The company plans to continue advancing multiple product pipelines and deepen its international strategic layout in 2026 to achieve rapid revenue growth [1] - Efforts will be made to enhance management efficiency and reduce operational costs across production, supply chain, marketing, and operational management to meet long-term strategic development goals [1]
健世科技-B预计年度总收入约1.05亿至1.1亿元